We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+0.75%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.44B
AUM Growth
-$102M
Cap. Flow
-$54M
Cap. Flow %
-2.21%
Top 10 Hldgs %
38.65%
Holding
187
New
10
Increased
35
Reduced
38
Closed
19

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$45.2M
2
HUM icon
Humana
HUM
+$23.9M
3
LLY icon
Eli Lilly
LLY
+$20.3M
4
ILMN icon
Illumina
ILMN
+$20.1M
5
ABT icon
Abbott
ABT
+$17.5M

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$44.1M
2
UNH icon
UnitedHealth
UNH
+$23.9M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$23.1M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$21.7M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$21.3M

Sector Composition

Rank Sector Weight
1 Healthcare 96.9%
2 Real Estate 1.86%
3 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
A icon
76
Agilent Technologies
A
$39.5B
$5.25M 0.21%
43,191
– –
XNCR icon
77
Xencor
XNCR
$1.44B
$5.21M 0.21%
200,328
-36,668
-15% -$1.05M
ARWR icon
78
Arrowhead Research
ARWR
$12.1B
$5.18M 0.21%
156,875
– –
CERE
79
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$4.99M 0.2%
176,483
+88,310
+100% +$2.63M
MPT
80
Medical Properties Trust
MPT
$2.75B
$4.88M 0.2%
411,743
– –
SNY icon
81
Sanofi
SNY
$103B
$4.69M 0.19%
123,454
– –
DSGN icon
82
Design Therapeutics
DSGN
$799M
$4.69M 0.19%
280,523
+172,109
+159% +$3.42M
VECT
83
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$4.54M 0.19%
756,502
– –
BCRX icon
84
BioCryst Pharmaceuticals
BCRX
$2.24B
$4.41M 0.18%
349,570
+72,136
+26% +$928K
SNN icon
85
Smith & Nephew
SNN
$13.5B
$4.22M 0.17%
181,710
– –
CCXI
86
DELISTED
ChemoCentryx, Inc.
CCXI
$4.04M 0.17%
78,197
– –
ALGN icon
87
Align Technology
ALGN
$12.4B
$3.91M 0.16%
18,894
– –
IONS icon
88
Ionis Pharmaceuticals
IONS
$9.06B
$3.88M 0.16%
87,840
-87,840
-50% -$3.7M
ARVN icon
89
Arvinas
ARVN
$520M
$3.83M 0.16%
85,997
– –
RCM
90
DELISTED
R1 RCM Inc. Common Stock
RCM
$3.75M 0.15%
202,351
– –
TEVA icon
91
Teva Pharmaceuticals
TEVA
$40.2B
$3.71M 0.15%
459,651
– –
HR icon
92
Healthcare Realty
HR
$7.12B
$3.64M 0.15%
174,686
+104,024
+147% +$2.64M
CYTK icon
93
Cytokinetics
CYTK
$10.4B
$3.64M 0.15%
75,139
-44,759
-37% -$2.15M
CRSP icon
94
CRISPR Therapeutics
CRSP
$4.88B
$3.6M 0.15%
55,080
– –
XLV icon
95
State Street Health Care Select Sector SPDR ETF
XLV
$41.8B
$3.52M 0.14%
29,024
-84,206
-74% -$10.8M
DOC icon
96
Healthpeak Properties
DOC
$14.9B
$3.45M 0.14%
150,392
– –
MRUS
97
DELISTED
Merus
MRUS
$3.39M 0.14%
169,207
+73,917
+78% +$1.76M
ADPT icon
98
Adaptive Biotechnologies
ADPT
$3.68B
$3.01M 0.12%
422,281
+84,559
+25% +$796K
IBB icon
99
iShares Biotechnology ETF
IBB
$9.18B
$2.87M 0.12%
+24,569
New +$3.05M
ARQT icon
100
Arcutis Biotherapeutics
ARQT
$3.24B
$2.85M 0.12%
148,874
– –
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Tekla Capital Management held 187 positions worth $2.44B, down 4% from $2.54B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q3 2022 filing shows 10 new, 35 increased, 38 reduced and 19 closed positions. Its largest new stake was Veradigm Inc. Common Stock: 428,580 shares worth $6.53M. The largest sale was McKesson, an estimated $44.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q3 2022 buy was Veradigm Inc. Common Stock: 428,580 shares worth $6.53M.
  • Tekla Capital Management added most to Johnson & Johnson in Q3 2022, an estimated $45.2M increase.
  • Tekla Capital Management's biggest Q3 2022 reduction was McKesson, cutting an estimated $44.1M.
  • Tekla Capital Management fully exited Syneos Health, Inc. Class A Common Stock in Q3 2022, selling an estimated $21.7M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.44B portfolio in Q3 2022.
  • Tekla Capital Management opened 10 new positions and closed 19 in Q3 2022.
  • Tekla Capital Management's portfolio value fell 4% quarter-over-quarter to $2.44B.

Based on Tekla Capital Management's 13F filing for Q3 2022, filed 1 Nov 2022.